Expert Interview
Reviewing the data from Supernus Pharmaceuticals exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder.
Ticker(s): SUPNInstitution: University of Minnesota
- Interventional Psychiatrist and Assistant Professor with the Department of Psychiatry for the University of Minnesota Medical School.
- Manages 80 patients with treatment resistant depression and has personally treated 40-50 psychiatric DBS patients, including patients who have been in Abbott's prior BROADEN trial.
- Research interests include deep brain stimulation, vagus nerve stimulation and transcranial magnetic stimulation and has written numerous review articles on these topics.
How many patients with MDD do you manage?
Added By: ben_adminWhat is the standard of care for MDD?
Added By: ben_adminWhat are the pros/cons of targeting mTORC1 in MDD patients?
Added By: ben_adminWhat are your impressions of the open label Phase2a data of SPN-820?
Added By: ben_adminWhat are your expectations for the ongoing randomized, double blind phase 2 study of SPN-820?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
